Episode Details

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biology, ethical sourcing, and manufacturing profile of human trophoblast stem cells. In Part 2, the conversation shifts to the larger ambition: using those cells not just to treat disease, but to slow, stop, or reverse biological aging itself. The evidence starts with a striking finding from the National Institute on Aging, and it builds from there.

Topics discussed:

• The science and ethics of sourcing stem cells from ectopic pregnancies (03:02)
• Differences in differentiation potential between very early-stage cells and traditional MSCs or iPSCs (05:09)
• The origins of the research focus, driven by NIH/NIA inquiry and lessons from Stanford parabiosis studies (07:27)
• Explanation of senescent cells, inflammation, and disease connections (08:51)
• Potential therapeutic scope, from neurodegeneration to autoimmune diseases, and systemic anti-inflammatory applications (09:26)
• Vision for aging prevention—possibility of maintaining young biological age through regular secretome therapy (10:21)
• Challenges and global differences in regulation, access, and clinical adoption (12:05)
• The realistic limits and potential for reversing versus preventing age-related damage (13:20)
• The future landscape of cell and gene therapy in medicine (14:20)
• Why more investment is needed in longevity science and therapeutics (16:25)
• Practical takeaways for listeners about improving healthspan and longevity today (18:07)

Smart insight:

Prevention is becoming the new frontier of medicine, shifting from treating disease to preserving long-term biological function. Yuta Lee highlights a future where proactive longevity strategies, from lifestyle choices to emerging biotech, could keep us healthier for longer and push toward “escape velocity” against aging.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

• Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
• Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
• Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
• Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show